Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhythmias was compared in a model of acute regional myocardial ischemia and reperfusion. The left anterior descending coronary artery in dogs was occluded for 25 minutes, followed by reperfusion. The 2 drugs were administered in a hemodynamically equieffective dose (0.1 μmol/kg) 10 minutes before coronary occlusion. Levosimendan, but not milrinone, significantly attenuated the pronounced increase in the number of ventricular premature beats (-63%), tachycardia (-50%), fibrillation (-70%), and inhomogeneity of ventricular electrical activation. Levosimendan significantly improved the overall survival rate. Levosimendan has a more beneficial profile than milrinone regarding the development of ventricular arrhythmias during and after regional myocardial ischemia
Papp Z, Csapo K, Pollesello P, Haikala H, Edes I.Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;3:71-98.
2.
Kivikko M, Lehtonen L.Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005;11:435-455.
3.
Szilagyi S, Pollesello P, Levijoki J, et al.The effects of levosimendan and OR-1896 on isolated hearts, myocytesized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67-74.
4.
Cuffe MS, Califf RM, Adams KF Jr, et al.Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
5.
Packer M, Carver JR, Rodeheffer RJ, et al.Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325: 1468-1475.
6.
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R.A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677-683.
7.
Felker GM, Benza RL, Chandler AB, et al.Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003.
8.
Poole-Wilson PA, Xue SR.New therapies for the management of acute heart failure. Curr Cardiol Rep. 2003; 5:229-236.
9.
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857-865.
10.
Benza RL, Tallaj JA, Felker GM, et al.The impact of arrhythmias in acute heart failure. J Card Fail. 2004;10: 279-284.
11.
Wang TJ, Larson MG, Levy D, et al.Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.
12.
Whang W, Mittleman MA, Rich DQ, et al.Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. Circulation. 2004; 109:1386-1391.
13.
Kies P, Boersma E, Bax JJ, et al.Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the leiden out-of-hospital cardiac arrest study. J Cardiovasc Electrophysiol. 2005;16:1049-1056.
14.
Macchia A, Levantesi G, Franzosi MG, et al.Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005; 7:904-909.
15.
Lilleberg J, Ylonen V, Lehtonen L, Toivonen L.The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 2004;38:80-84.
16.
Vegh A, Komori S, Szekeres L, Parratt JR.Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res. 1992;26:487-495.
17.
Rastegar MA, Marchini F, Morazzoni G, Vegh A, Papp JG, Parratt JR.The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000;129:671-680.
18.
Nieminen MS, Akkila J, Hasenfuss G, et al.Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-1912.
19.
Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr.Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology. 1994;81: 616-622.
20.
Du Toit EF, Muller CA, McCarthy J, Opie LH.Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther. 1999;290:505-514.
21.
Levijoki J, Pollesello P, Kaheinen P, Haikala H.Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol. 2001; 419:243-248.
22.
Lepran I, Papp JG.Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats. Eur J Pharmacol. 2003;464:171-176.
23.
Maury P, Baixas C, Roncalli J, et al.Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node. Pacing Clin Electrophysiol. 2004;27: 1314-1316.
24.
Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L.Electrophysiologic effects of a calcium sensitizerinotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol. 2000;35: 664-669.
25.
Moiseyev VS, Poder P, Andrejevs N, et al.Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
26.
Kersten JR, Montgomery MW, Pagel PS, Warltier DC, et al.Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
Rump AF, Acar D, Rosen R, Klaus W.Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol. 1994;74:244-248.
29.
Kaheinen P, Pollesello P, Levijoki J, Haikala H.Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43:555-561.
30.
Eriksson O, Pollesello P, Haikala H.Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol. 2004;44:316-321.
31.
Ukkonen H, Saraste M, Akkila J, et al.Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-531.
32.
Kopustinskiene DM, Pollesello P, Saris NE.Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68:807-812.
33.
Vegh A, Parratt JR.The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs. Br J Pharmacol. 2002;137: 1107-1115.
